Higenamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Higenamine
Accession Number
DB12779
Type
Small Molecule
Groups
Investigational
Description

Higenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
TBV5O16GAP
CAS number
5843-65-2
Weight
Average: 271.3111
Monoisotopic: 271.120843415
Chemical Formula
C16H17NO3
InChI Key
WZRCQWQRFZITDX-UHFFFAOYSA-N
InChI
InChI=1S/C16H17NO3/c18-12-3-1-10(2-4-12)7-14-13-9-16(20)15(19)8-11(13)5-6-17-14/h1-4,8-9,14,17-20H,5-7H2
IUPAC Name
1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol
SMILES
OC1=CC=C(CC2NCCC3=C2C=C(O)C(O)=C3)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Higenamine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Higenamine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Higenamine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Higenamine is combined with 5-androstenedione.Experimental, Illicit
AbciximabHigenamine may increase the anticoagulant activities of Abciximab.Approved
AcebutololHigenamine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Higenamine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Higenamine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolHigenamine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Higenamine.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Higenamine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Higenamine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
AliskirenHigenamine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Higenamine.Experimental
AlprenololHigenamine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Higenamine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Amcinonide.Approved
AmilorideHigenamine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Higenamine is combined with Aminosalicylic Acid.Approved
AmitriptylineAmitriptyline may decrease the vasoconstricting activities of Higenamine.Approved
AmoxapineAmoxapine may decrease the vasoconstricting activities of Higenamine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Higenamine.Approved
AncrodHigenamine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Higenamine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Higenamine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Higenamine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Higenamine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Higenamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Higenamine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanHigenamine may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Higenamine is combined with Antrafenine.Approved
ApixabanHigenamine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Higenamine.Investigational
ApramycinHigenamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Higenamine.Approved, Investigational
AprotininThe therapeutic efficacy of Higenamine can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArbekacinHigenamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinHigenamine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanHigenamine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
ArotinololHigenamine may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineAsenapine may decrease the vasoconstricting activities of Higenamine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Higenamine is combined with Atamestane.Investigational
AtenololHigenamine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Higenamine.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Higenamine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Higenamine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Higenamine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Higenamine.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Higenamine is combined with Balsalazide.Approved, Investigational
BecaplerminHigenamine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololHigenamine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinHigenamine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Higenamine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Higenamine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Higenamine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Higenamine.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Higenamine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Benzydamine.Approved
Benzylpenicilloyl PolylysineHigenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Higenamine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Betamethasone.Approved, Vet Approved
BetaxololHigenamine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Higenamine.Approved, Investigational
BevantololHigenamine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Higenamine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Higenamine.Approved, Investigational
BisoprololHigenamine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinHigenamine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololHigenamine may decrease the antihypertensive activities of Bopindolol.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Higenamine is combined with Bromfenac.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Higenamine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Higenamine.Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Higenamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Higenamine is combined with Bufexamac.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Higenamine.Experimental
BufuralolHigenamine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Higenamine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Higenamine.Investigational
BupranololHigenamine may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Higenamine.Investigational
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Higenamine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Higenamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Higenamine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Higenamine is combined with Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Higenamine.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Higenamine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Higenamine.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Higenamine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololHigenamine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe therapeutic efficacy of Higenamine can be decreased when used in combination with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Higenamine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Celecoxib.Approved, Investigational
CeliprololHigenamine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinHigenamine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Higenamine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Higenamine.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Higenamine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Higenamine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Higenamine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Higenamine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Cimicoxib.Investigational
CinoxacinHigenamine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Higenamine is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Higenamine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Higenamine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Higenamine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Higenamine.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Higenamine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Higenamine.Vet Approved
CloranololHigenamine may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenCloricromen may increase the anticoagulant activities of Higenamine.Experimental
ClozapineClozapine may decrease the vasoconstricting activities of Higenamine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Higenamine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Higenamine is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Higenamine.Approved, Investigational
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Higenamine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Higenamine.Experimental
Dabigatran etexilateHigenamine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinHigenamine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidHigenamine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Higenamine.Approved
DarexabanHigenamine may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Higenamine is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Higenamine.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Higenamine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Delapril.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Higenamine.Investigational
DesipramineHigenamine may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinHigenamine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Higenamine.Approved, Investigational
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Higenamine is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Higenamine.Approved, Investigational
DextranHigenamine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Higenamine.Approved, Illicit
DibekacinHigenamine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Higenamine is combined with Dibotermin alfa.Approved, Investigational
DicoumarolHigenamine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Higenamine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Higenamine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Higenamine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Higenamine.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Higenamine.Approved, Investigational
DihydrostreptomycinHigenamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Higenamine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Higenamine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Higenamine.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Higenamine.Approved
DoxazosinThe therapeutic efficacy of Higenamine can be decreased when used in combination with Doxazosin.Approved
DoxepinDoxepin may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
DronedaroneDronedarone may decrease the vasoconstricting activities of Higenamine.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Higenamine.Approved, Vet Approved
DrospirenoneHigenamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Higenamine is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the tachycardic activities of Higenamine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Higenamine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Higenamine.Investigational
Edetic AcidHigenamine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanHigenamine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Higenamine is combined with Enalaprilat.Approved
EnoxacinHigenamine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinHigenamine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Higenamine.Experimental
EpanololHigenamine may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Higenamine.Approved, Investigational
EpinephrineEpinephrine may decrease the vasoconstricting activities of Higenamine.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Higenamine.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Higenamine.Experimental
EplerenoneHigenamine may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Higenamine.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Higenamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Higenamine.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Higenamine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Higenamine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Higenamine is combined with Equilin.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Higenamine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Higenamine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Higenamine.Approved
EsatenololHigenamine may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
EsmololHigenamine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Higenamine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Higenamine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Higenamine is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Higenamine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateHigenamine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Higenamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Higenamine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Higenamine.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Higenamine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Higenamine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Higenamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Higenamine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Higenamine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Feprazone.Experimental
Ferulic acidHigenamine may increase the anticoagulant activities of Ferulic acid.Experimental
FleroxacinHigenamine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Higenamine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fludrocortisone.Approved, Investigational
FluindioneHigenamine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineHigenamine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Higenamine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Higenamine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluorometholone.Approved, Investigational
FlupentixolFlupentixol may decrease the vasoconstricting activities of Higenamine.Approved, Investigational, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Higenamine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Higenamine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluticasone furoate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Higenamine.Approved, Nutraceutical, Vet Approved
FondaparinuxHigenamine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Higenamine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Higenamine is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinHigenamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateHigenamine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinHigenamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinHigenamine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Higenamine.Approved, Withdrawn
GemifloxacinHigenamine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinHigenamine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinHigenamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AHigenamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Higenamine is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinHigenamine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Higenamine.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Higenamine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Higenamine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Higenamine is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Higenamine.Experimental
HeparinHigenamine may increase the anticoagulant activities of Heparin.Approved, Investigational
HydralazineHigenamine may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Higenamine.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Higenamine.Investigational
Hygromycin BHigenamine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbudilastIbudilast may increase the anticoagulant activities of Higenamine.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Higenamine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Higenamine.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Higenamine is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Higenamine.Approved, Investigational, Nutraceutical
IdraparinuxHigenamine may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Higenamine.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Higenamine.Investigational
IloperidoneIloperidone may decrease the vasoconstricting activities of Higenamine.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Higenamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Higenamine is combined with Imidazole salicylate.Experimental
ImipramineImipramine may decrease the vasoconstricting activities of Higenamine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Higenamine.Approved
IndenololHigenamine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Higenamine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Higenamine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Higenamine.Withdrawn
IndoraminIndoramin may decrease the vasoconstricting activities of Higenamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Higenamine.Approved, Investigational
IsepamicinHigenamine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Higenamine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Higenamine is combined with Istaroxime.Investigational
KanamycinHigenamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Higenamine.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Higenamine.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Ketoprofen.Approved, Vet Approved
LabetalolThe therapeutic efficacy of Higenamine can be decreased when used in combination with Labetalol.Approved
LandiololHigenamine may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Higenamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Higenamine.Approved, Investigational
LepirudinHigenamine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanHigenamine may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololHigenamine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololHigenamine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinHigenamine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Higenamine.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Higenamine.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Higenamine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Higenamine.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Higenamine.Experimental
LomefloxacinHigenamine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Higenamine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Higenamine is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Higenamine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Higenamine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Higenamine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Higenamine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Higenamine is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Higenamine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Higenamine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Mefenamic acid.Approved
MelagatranHigenamine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Higenamine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Higenamine is combined with Meloxicam.Approved, Vet Approved
MepindololHigenamine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Higenamine is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Higenamine.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Higenamine.Approved
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Higenamine.Approved
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Higenamine.Approved
MetipranololHigenamine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Higenamine.Approved
MetoprololThe therapeutic efficacy of Higenamine can be decreased when used in combination with Metoprolol.Approved, Investigational
MicronomicinHigenamine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Higenamine.Approved, Experimental
MilnacipranMilnacipran may increase the tachycardic activities of Higenamine.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Higenamine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Higenamine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Higenamine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Higenamine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Higenamine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Higenamine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Nabumetone.Approved
NadololHigenamine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinHigenamine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatHigenamine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Higenamine.Approved
Nalidixic AcidHigenamine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Higenamine is combined with NCX 1022.Investigational
NeamineHigenamine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololHigenamine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Higenamine.Approved, Withdrawn
NemonoxacinHigenamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Higenamine is combined with Nepafenac.Approved, Investigational
NetilmicinHigenamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Higenamine is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Niguldipine.Experimental
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Higenamine.Investigational
NorfloxacinHigenamine may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineNortriptyline may decrease the vasoconstricting activities of Higenamine.Approved
OfloxacinHigenamine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineOlanzapine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Higenamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Higenamine.Approved
OlsalazineHigenamine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Higenamine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Higenamine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Higenamine.Vet Approved
OtamixabanHigenamine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Higenamine is combined with Oxaprozin.Approved
Oxolinic acidHigenamine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololHigenamine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Higenamine.Approved, Withdrawn
PaliperidonePaliperidone may decrease the vasoconstricting activities of Higenamine.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Higenamine is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Higenamine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Higenamine is combined with Parthenolide.Approved, Investigational
PazufloxacinHigenamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinHigenamine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololHigenamine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateHigenamine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateHigenamine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Higenamine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Perindopril.Approved
PhenindioneHigenamine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Higenamine.Approved
PhenprocoumonHigenamine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolaminePhentolamine may decrease the vasoconstricting activities of Higenamine.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Higenamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Phenylbutazone.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Higenamine.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Higenamine.Approved, Investigational
PindololHigenamine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidHigenamine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Higenamine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Higenamine.Approved, Investigational
Piromidic acidHigenamine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Higenamine is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Higenamine is combined with Pitolisant.Approved, Investigational
PizotifenPizotifen may decrease the vasoconstricting activities of Higenamine.Approved
Platelet Activating FactorHigenamine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinHigenamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Higenamine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Higenamine is combined with Pomalidomide.Approved
Potassium CitrateHigenamine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololHigenamine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Higenamine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Higenamine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Higenamine is combined with Prasterone sulfate.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Higenamine.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Higenamine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Higenamine can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Higenamine is combined with Proglumetacin.Experimental
PromazinePromazine may decrease the vasoconstricting activities of Higenamine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Higenamine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Higenamine can be decreased when used in combination with Propafenone.Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Higenamine.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
PropranololThe therapeutic efficacy of Higenamine can be decreased when used in combination with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Higenamine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Higenamine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Higenamine.Vet Approved
Protein CHigenamine may increase the anticoagulant activities of Protein C.Approved
Protein S humanHigenamine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeHigenamine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinHigenamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Higenamine.Investigational
PuromycinHigenamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuetiapineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Higenamine.Approved
QuinidineQuinidine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Higenamine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Higenamine.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Ramipril.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Higenamine.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Higenamine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinHigenamine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinHigenamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Higenamine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Higenamine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
RivaroxabanHigenamine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinHigenamine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinHigenamine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Higenamine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Higenamine.Approved
SalsalateThe risk or severity of adverse effects can be increased when Higenamine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Higenamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Higenamine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Higenamine.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Higenamine.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Higenamine is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Higenamine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Higenamine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Higenamine is combined with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Higenamine.Approved, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Higenamine.Approved
SisomicinHigenamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinHigenamine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolHigenamine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinHigenamine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Spirapril.Approved
SpironolactoneThe therapeutic efficacy of Higenamine can be decreased when used in combination with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Higenamine.Investigational
StreptomycinHigenamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulodexideHigenamine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Higenamine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Higenamine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Higenamine is combined with Suxibuzone.Experimental
TacrolimusHigenamine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Higenamine.Approved
TalinololHigenamine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Higenamine.Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Higenamine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Higenamine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Higenamine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Higenamine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Higenamine.Approved, Investigational
TemafloxacinHigenamine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Higenamine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Higenamine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Higenamine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Higenamine.Vet Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Higenamine.Approved
TerbutalineHigenamine may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Higenamine.Approved
TertatololHigenamine may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the anticoagulant activities of Higenamine.Investigational
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Higenamine.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Higenamine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Tiaprofenic acid.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Higenamine.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Higenamine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Higenamine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololHigenamine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Higenamine is combined with Tinoridine.Investigational
TirofibanTirofiban may increase the anticoagulant activities of Higenamine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Higenamine is combined with Tixocortol.Approved, Withdrawn
TobramycinHigenamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazolineTolazoline may decrease the vasoconstricting activities of Higenamine.Approved, Vet Approved
TolmetinThe risk or severity of adverse effects can be increased when Higenamine is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Higenamine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Trandolapril.Approved
TrapidilTrapidil may increase the anticoagulant activities of Higenamine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Higenamine.Approved
TrazodoneTrazodone may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Higenamine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Higenamine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneHigenamine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Higenamine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Higenamine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Higenamine.Approved, Investigational
TrimazosinTrimazosin may decrease the vasoconstricting activities of Higenamine.Experimental
TrimipramineTrimipramine may decrease the vasoconstricting activities of Higenamine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Higenamine.Investigational
TrovafloxacinHigenamine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinHigenamine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Higenamine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Higenamine.Approved, Investigational
UrapidilUrapidil may decrease the vasoconstricting activities of Higenamine.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Higenamine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Higenamine.Approved, Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Higenamine.Approved
VerapamilThe therapeutic efficacy of Higenamine can be decreased when used in combination with Verapamil.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Higenamine.Approved
WarfarinHigenamine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranHigenamine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Higenamine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Higenamine.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Higenamine.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Higenamine is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Higenamine.Withdrawn
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Higenamine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0033103
KEGG Compound
C06346
PubChem Compound
114840
PubChem Substance
347828960
ChemSpider
102800
ChEBI
18418
ChEMBL
CHEMBL19344
Wikipedia
Higenamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.236 mg/mLALOGPS
logP1.73ALOGPS
logP2.23ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)8.75ChemAxon
pKa (Strongest Basic)9.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.6 m3·mol-1ChemAxon
Polarizability29.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0190000000-96f0438a3c8200e429fa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-074r-0950000000-0a5c9c204527cfedca3e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-3900000000-d9dc7703828981b3c07c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0090000000-22dffcee90bf3f5ca3cc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0190000000-0fea9c480c329f5a864d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-1910000000-1d1e1af6c74b76f1bc5b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Tetrahydroisoquinolines / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Benzylisoquinoline / Tetrahydroisoquinoline / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Secondary aliphatic amine / Secondary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
norcoclaurine (CHEBI:18418)

Drug created on October 20, 2016 18:11 / Updated on August 02, 2018 06:43